A
Akiko Saga-Kamo
Researcher at University of Tokyo
Publications - 5
Citations - 213
Akiko Saga-Kamo is an academic researcher from University of Tokyo. The author has contributed to research in topics: Internal medicine & Angiotensin II. The author has an hindex of 2, co-authored 3 publications receiving 132 citations.
Papers
More filters
Journal ArticleDOI
Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure
Takehiro Kamo,Hiroshi Akazawa,Wataru Suda,Wataru Suda,Akiko Saga-Kamo,Yu Shimizu,Hiroki Yagi,Qing Liu,Seitaro Nomura,Atsuhiko T. Naito,Norifumi Takeda,Mutsuo Harada,Haruhiro Toko,Hidetoshi Kumagai,Yuichi Ikeda,Eiki Takimoto,Jun-ichi Suzuki,Kenya Honda,Hidetoshi Morita,Masahira Hattori,Masahira Hattori,Issei Komuro +21 more
TL;DR: It is suggested that patients with HF harbor significantly altered gut microbiota, which varies further according to age, and new concept of heart-gut axis has a great potential for breakthroughs in the development of novel diagnostic and therapeutic approach for HF.
Journal ArticleDOI
Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression
Chizuru Yabumoto,Hiroshi Akazawa,Rie Yamamoto,Masamichi Yano,Yoko Kudo-Sakamoto,Tomokazu Sumida,Tomokazu Sumida,Takehiro Kamo,Hiroki Yagi,Yu Shimizu,Akiko Saga-Kamo,Atsuhiko T. Naito,Atsuhiko T. Naito,Atsuhiko T. Naito,Toru Oka,Toru Oka,Jong-Kook Lee,Jun-ichi Suzuki,Yasushi Sakata,Etsuko Uejima,Issei Komuro,Issei Komuro +21 more
TL;DR: The results suggest that AT1 receptor blockade improves muscle repair and regeneration through down-regulation of the aging-promoting C1q-Wnt/β-catenin signaling pathway.
Journal ArticleDOI
Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors
Hiroshi Kadowaki,Junichi Ishida,Hiroshi Akazawa,Hiroki Yagi,Akiko Saga-Kamo,Masahiko Umei,Ryo Matsuoka,Qing Liu,Hiroshi Matsunaga,Hisataka Maki,Yusuke Sato,Haruki Kume,Issei Komuro +12 more
TL;DR: In this paper, a single-center retrospective study, advanced renal cell carcinoma (RCC) patients treated with axitinib after first-line chemotherapy were divided into two groups according to the use of tyrosine kinase kinase inhibitor (TKI) as part of first-linearly treatment before the initiation of axinib.
Posted ContentDOI
Aberrant mechanosensitive signaling underlies activation of vascular endothelial xanthine oxidoreductase that promotes aortic aneurysm formation in Marfan syndrome
Hiroki Yagi,Hiroshi Akazawa,Qing Liu,Kimiko Yamamoto,Kan Nawata,Akiko Saga-Kamo,Masahiko Umei,Hiroshi Kadowaki,Ryo Matsuoka,Akito Shindo,Haruhiro Toko,Norifumi Takeda,Masahiko Ando,Haruo Yamauchi,Norihiko Takeda,Mehdi A. Fini,Minoru Ono,Issei Komuro +17 more
TL;DR: Findings unveil aberrant mechanosensitive signaling in vascular ECs triggering endothelial XOR activation and ROS generation as a culprit underlying the pathogenesis of aortic aneurysm formation in MFS, and highlight a drug repositioning approach using a uric acid lowering drug febuxostat as a potential therapy for MFS.
Posted ContentDOI
Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Aortic Aneurysm Formation in Marfan Syndrome
Hiroki Yagi,Hiroshi Akazawa,Qing Liu,Masahiko Umei,Hiroshi Kadowaki,Ryo Matsuoka,Akito Shindo,Shun Okamura,Akiko Saga-Kamo,Norifumi Takeda,Issei Komuro +10 more
TL;DR: In this article , aortic aneurysm formation was detected in mice with MFS using echocardiography, histological staining, and in situ MMP assay.